PRESENCE AND CHARACTERISTICS OF RECEPTORS FOR [D-TRP(6)]LUTEINIZING HORMONE-RELEASING HORMONE AND EPIDERMAL GROWTH-FACTOR IN HUMAN OVARIAN-CANCER

This study was undertaken to establish the presence and characteristic s of receptors for [D-Trp(6)]LH-RH on the membranes of human ovarian c ancer. Specific binding of [I-125, D-Trp(6)]LH-RH was found in 29 of 3 7 (78.4%) ovarian cancers and in 6 of 11 (54.5%) non-malignant human o varies. Ligand binding was dependent on time and plasma membrane conce ntration in a fashion expected of a peptide hormone. Saturation, kinet ic and displacement data were consistent with the presence of a highly specific, single class of non-cooperative binding site. On the basis of receptors affinity, LH-RH-receptor-positive ovarian cancers could b e divided into two groups: high affinity group (K-d=2.7+/-0.60 nM; B-m ax=0.46+/-0.07 pmol/mg membrane protein) comprising 55% of tumors, and low affinity group (K-d=78.0+/-19.6 nM; B-max=9.44+/-2.68 pmol/mg mem brane protein) which included 45% of tumors. LH-RH antagonist Cetrorel ix showed an affinity to LH-RH receptors on ovarian cancers 14 times h igher than the agonist [D-Trp(6)]LH-RH. Using I-125-epidermal growth f actor, specific high affinity receptors were also detected in membrane s from 13 of 24 (54%) ovarian cancers and 5 of 11 (45%) non-malignant ovaries. The demonstration of LH-RH receptors in human ovarian cancers provides a rationale for the use of therapeutic approaches based on L H-RH analogues in this malignancy. The probable involvement of growth factors in the development of ovarian cancers suggests the merit of tr ying a combined therapy based on analogs of LH-RH and somatostatin for this carcinoma.